Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Vericel Corporation (VCEL)
USD46.24
-1.26 (-2.64%)
US NASDAQ Healthcare Biotechnology
Address
64 Sidney Street 2139
Cambridge, MA, US
Cambridge, MA, US
CEO
Dominick C. Colangelo
Website
vcel.com
IPO
1997-02-04
CIK 887359 ISIN US92346J1088
Description
Vericel Corporation operates as a biopharmaceutical firm that has reached the commercialization phase, specializing in the research, development, production, and distribution of cell-based treatments. Its primary therapeutic areas are sports medicine and critical burn care across the United States. The company's product lineup includes MACI, an autologous cellularized scaffold employed for mending symptomatic, full-thickness cartilage damage in the knee, and Epicel, a permanent skin replacement designated as a humanitarian use device for treating deep-dermal or full-thickness burns in both adults and children. Additionally, Vericel is progressing NexoBrid, an orphan biological product currently in the registration phase, which aims to remove eschar from deep partial-thickness or full-thickness thermal burns in adults. Established in 1989 under its former name, Aastrom Biosciences, Inc., the company is headquartered in Cambridge, Massachusetts.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD46.24
-1.26 (-2.64%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
640.3K
Beta
1.13
Float Shares
50.30M
Free Float %
98.8%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.61% | -18.72% | -2.31% | -3.09% | -18.60% | -8.58% | -22.81% | +0.40% | -30.25% | +1,023.55% | -97.06% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (14 ratings, all time)
Buy
Price Targets & DCF
Current price
46.24
Low
42.00
-9.2%
Consensus
52.67
+13.9%
Median
46.00
-0.5%
High
70.00
+51.4%
DCF (Levered)
7.96
-82.8%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
88% Bullish
| Rating | 2026-05 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 7 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Price Target Summary
| Period | # Analysts | Avg Target |
|---|---|---|
| Last Month | 1 |
42.00
-9.2%
|
| Last Quarter | 2 |
44.00
-4.8%
|
| Last Year | 4 |
43.50
-5.9%
|
| All Time | 13 |
47.38
+2.5%
|
Quality scores
Altman Z-Score
7.92
Safe zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
3 / 10
No MOAT
Composite Rating
B-
Overall Score
3 / 5
Medium
DCF Score
3 / 5
Medium
ROE Score
3 / 5
Medium
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
2 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%+16.5% ★ Q1'26: +30.1% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+60.0% ★ Q1'26: +47.8% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-1.8% Q1'26: +22.1% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+6.9% ★ Q1'26: -11.8% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+5.7% ★ Q1'26: -10.6% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+0.8% ★ Q1'26: +1.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×3.24× ★ Q1'26: -4.92× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 5 Rev. Ana. 4 EPS Ana. |
Dec 2027 6 Rev. Ana. 4 EPS Ana. |
Dec 2028 6 Rev. Ana. 5 EPS Ana. |
Dec 2029 5 Rev. Ana. 1 EPS Ana. |
Dec 2030 3 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
51.17M
est: 53.08M (-3.6%)
|
54.38M
est: 53.94M (+0.8%)
|
63.92M
est: 59.16M (+8.1%)
|
90.86M
est: 88.22M (+3.0%)
|
117.85M
est: 117.45M (+0.3%)
|
124.18M
est: 123.94M (+0.2%)
|
156.18M
est: 157.58M (-0.9%)
|
164.37M
est: 164.57M (-0.1%)
|
197.52M
est: 214.52M (-7.9%)
|
237.22M
est: 238.38M (-0.5%)
|
276.26M
est: 274.37M (+0.7%)
|
332.18M
332.07M – 332.27M
+21.1% YoY
|
388.62M
385.53M – 391.70M
+17.0% YoY
|
452.73M
451.58M – 453.88M
+16.5% YoY
|
522.04M
517.34M – 530.26M
+15.3% YoY
|
665.63M
659.64M – 676.11M
+27.5% YoY
|
| EBITDA |
-14.74M
est: 297.1K (-5,060.6%)
|
-17.37M
est: 301.9K (-5,852.0%)
|
-14.57M
est: 331.1K (-4,499.5%)
|
-4.98M
est: -2.72M (-82.9%)
|
-7.91M
est: 7.25M (-209.1%)
|
5.43M
est: 28.55M (-81.0%)
|
-4.61M
est: -3.77M (-22.3%)
|
-11.64M
est: -6.43M (-81.1%)
|
2.86M
est: 4.03M (-28.9%)
|
16.63M
est: 4.48M (+271.5%)
|
30.29M
est: 5.15M (+488.0%)
|
6.24M
6.24M – 6.24M
+21.1% YoY
|
7.30M
7.24M – 7.36M
+17.0% YoY
|
8.50M
8.48M – 8.52M
+16.5% YoY
|
9.80M
9.71M – 9.96M
+15.3% YoY
|
12.50M
12.39M – 12.70M
+27.5% YoY
|
| EBIT |
-16.33M
est: -860.6K (-1,797.6%)
|
-19.25M
est: -874.5K (-2,101.5%)
|
-16.18M
est: -959.1K (-1,587.0%)
|
-6.41M
est: -3.76M (-70.1%)
|
-9.66M
est: 543.0K (-1,878.4%)
|
3.05M
est: 14.85M (-79.5%)
|
-7.58M
est: -7.36M (-3.0%)
|
-15.62M
est: -10.19M (-53.3%)
|
-1.77M
est: -1.59M (-11.1%)
|
11.12M
est: -1.77M (+729.1%)
|
18.93M
est: -2.04M (+1,030.2%)
|
-2.46M
-2.46M – -2.46M
-21.1% YoY
|
-2.88M
-2.91M – -2.86M
-17.0% YoY
|
-3.36M
-3.37M – -3.35M
-16.5% YoY
|
-3.87M
-3.93M – -3.84M
-15.3% YoY
|
-4.94M
-5.02M – -4.89M
-27.5% YoY
|
| Net Income |
-16.34M
est: -43.15M (+62.1%)
|
-19.57M
est: -48.75M (+59.9%)
|
-17.29M
est: -31.27M (+44.7%)
|
-8.14M
est: -5.71M (-42.5%)
|
-9.67M
est: 3.61M (-367.6%)
|
2.86M
est: 15.72M (-81.8%)
|
-7.47M
est: -6.80M (-9.8%)
|
-16.71M
est: -13.17M (-26.9%)
|
-3.18M
est: 858.6K (-470.6%)
|
10.36M
est: 7.11M (+45.8%)
|
16.52M
est: 14.86M (+11.2%)
|
23.91M
19.14M – 30.62M
+61.0% YoY
|
41.04M
36.17M – 50.40M
+71.6% YoY
|
65.69M
58.21M – 83.23M
+60.1% YoY
|
91.38M
90.31M – 93.25M
+39.1% YoY
|
117.68M
116.30M – 120.09M
+28.8% YoY
|
| SGA |
22.48M
est: 32.32M (-30.4%)
|
27.39M
est: 32.84M (-16.6%)
|
35.61M
est: 36.02M (-1.1%)
|
49.01M
est: 47.26M (+3.7%)
|
61.14M
est: 71.51M (-14.5%)
|
68.84M
est: 75.46M (-8.8%)
|
97.59M
est: 107.77M (-9.4%)
|
106.90M
est: 114.95M (-7.0%)
|
121.00M
est: 132.76M (-8.9%)
|
142.79M
est: 147.52M (-3.2%)
|
166.99M
est: 169.80M (-1.7%)
|
205.57M
205.50M – 205.62M
+21.1% YoY
|
240.50M
238.59M – 242.41M
+17.0% YoY
|
280.17M
279.46M – 280.88M
+16.5% YoY
|
323.07M
320.16M – 328.15M
+15.3% YoY
|
411.93M
408.22M – 418.41M
+27.5% YoY
|
| EPS |
-0.69
est: -0.84 (+17.4%)
|
-0.85
est: -0.94 (+9.9%)
|
-0.52
est: -0.61 (+14.0%)
|
-0.20
est: -0.27 (+27.0%)
|
-0.18
est: -0.23 (+22.3%)
|
0.06
est: 0.01 (+815.7%)
|
-0.16
est: -0.11 (-42.6%)
|
-0.35
est: -0.44 (+21.2%)
|
-0.07
est: 0.02 (-507.5%)
|
0.21
est: 0.14 (+54.8%)
|
0.33
est: 0.27 (+23.9%)
|
0.47
0.37 – 0.59
+77.5% YoY
|
0.88
0.69 – 0.97
+85.5% YoY
|
1.37
1.12 – 1.60
+56.6% YoY
|
1.76
1.73 – 1.79
+27.8% YoY
|
2.26
2.23 – 2.31
+28.8% YoY
|
Recent Grade Changes (3M)
| Date | Firm | Previous | New Grade | Action |
|---|---|---|---|---|
| 2026-04-15 | Truist Securities | Buy | Buy | Maintain |
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-07 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-06 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-05 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-04 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-05-01 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-30 | B- | 3/5 | 3/5 | 3/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-29 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-28 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-27 | B- | 2/5 | 3/5 | 2/5 | 4/5 | 2/5 | 1/5 | 2/5 |
| 2026-04-24 | B- | 2/5 | 3/5 | 3/5 | 4/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-23 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-22 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-21 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-20 | B- | 3/5 | 3/5 | 3/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-17 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-16 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
| 2026-04-15 | B- | 2/5 | 3/5 | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
85.89M
OE per share TTM
1.68
Owner's Yield
4.82%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
52.4%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
55
Total invested
179.70M
Insider transactions (90d)
6
Beneficial owners (>5%)
33
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Brown Capital Management, LLC | 5.79M | 12.37% | 3.69M | — | 5.79M | — | IA | — | 2022-02-14 | ↗ |
| 2 | RTW Investments, LP | 4.52M | 9.94% | — | 4.52M | — | 4.52M | IA, PN, OO | Delaware | 2021-02-12 | ↗ |
| 3 | Roderick Wong | 4.52M | 9.94% | — | 4.52M | — | 4.52M | HC, IN | Delaware | 2021-02-12 | ↗ |
| 4 | 13-3017981 | 3.20M | 6.80% | 3.20M | — | 3.20M | — | HC | New York | 2022-02-14 | ↗ |
| 5 | RTW Master Fund, Ltd. | 3.17M | 6.98% | — | 3.17M | — | 3.17M | CO | Delaware | 2021-02-12 | ↗ |
| 6 | The Brown Capital Management Small Company Fund | 3.14M | 6.70% | 3.14M | — | 3.14M | — | IV | — | 2022-02-14 | ↗ |
| 7 | (1) BlackRock, Inc. | 2.97M | 6.80% | 2.89M | — | 2.97M | — | HC | Delaware | 2019-02-08 | ↗ |
| 8 | STATE STREET CORPORATION | 2.81M | 6.00% | — | — | — | — | HC | — | 2022-02-10 | ↗ |
| 9 | Archon Capital Management LLC | 2.48M | 7.56% | — | 2.48M | — | 2.48M | IA, OO | United States | 2017-08-28 | ↗ |
| 10 | Constantinos Christofilis | 2.48M | 7.56% | — | 2.48M | — | 2.48M | IN | United States | 2017-08-28 | ↗ |
| 11 | Conestoga Capital Advisors LLC | 2.48M | 5.25% | 2.35M | — | 2.48M | — | IA | Delaware | 2023-01-19 | ↗ |
| 12 | Dr. Jeffrey R. Jay, M.D. | 2.17M | 9.99% | — | 2.17M | — | 2.17M | IN | USA | 2014-09-22 | ↗ |
| 13 | Great Point Partners, LLC | 2.17M | 9.99% | — | 2.17M | — | 2.17M | IA | USA | 2014-09-22 | ↗ |
| 14 | Mr. David Kroin | 2.17M | 9.99% | — | 2.17M | — | 2.17M | IN | USA | 2014-09-22 | ↗ |
| 15 | Jon M. Plexico | 1.88M | 5.90% | 1.88M | — | 1.88M | — | HC, IN | California | 2017-02-14 | ↗ |
| 16 | Stonepine Capital Management, LLC | 1.88M | 5.90% | 1.88M | — | 1.88M | — | IA, OO | California | 2017-02-14 | ↗ |
| 17 | Stonepine Capital, L.P. | 1.88M | 5.90% | 1.88M | — | 1.88M | — | PN | California | 2017-02-14 | ↗ |
| 18 | Timothy P. Lynch | 1.88M | 5.90% | 1.88M | — | 1.88M | — | HC, IN | California | 2017-02-14 | ↗ |
| 19 | EASTERN CAPITAL LIMITED | 1.88M | 5.50% | — | 1.88M | — | 1.88M | CO | CAYMAN ISLANDS | 2017-01-18 | ↗ |
| 20 | KENNETH B. DART | 1.88M | 5.50% | — | 1.88M | — | 1.88M | IN | CAYMAN ISLANDS | 2017-01-18 | ↗ |
| 21 | PORTFOLIO SERVICES LTD. | 1.88M | 5.50% | — | 1.88M | — | 1.88M | CO | CAYMAN ISLANDS | 2017-01-18 | ↗ |
| 22 | S | 1.76M | 5.04% | — | 1.76M | — | — | IA | Delaware, United States of America | 2018-01-18 | ↗ |
| 23 | Strategos Fund, L.P. | 1.70M | 5.18% | — | 1.70M | — | 1.70M | PN | United States | 2017-08-28 | ↗ |
| 24 | Consonance Capman GP LLC | 1.56M | 3.48% | — | 1.56M | — | — | HC, OO | Delaware, USA | 2020-02-14 | ↗ |
| 25 | Mitchell Blutt | 1.56M | 3.48% | — | 1.56M | — | — | HC, IN | Delaware, USA | 2020-02-14 | ↗ |
| 26 | Consonance Capital Management LP | 1.45M | 3.24% | — | 1.45M | — | — | IA, PN | Delaware, USA | 2020-02-14 | ↗ |
| 27 | 2 | 1.42M | 6.00% | — | 1.42M | — | 1.42M | CO | Cayman Islands | 2014-12-12 | ↗ |
| 28 | Consonance Capital Opportunity Fund Management LP | 109.5K | 0.24% | — | 109.5K | — | — | IA, PN | Delaware, USA | 2020-02-14 | ↗ |
| 29 | Company, L.P. | 64.9K | 0.14% | — | 64.9K | — | — | PN | — | 2021-02-12 | ↗ |
| 30 | Deerfield Mgmt, L.P. | 64.9K | 0.14% | — | 64.9K | — | — | PN | — | 2021-02-12 | ↗ |
| 31 | Deerfield Partners, L.P. | 64.9K | 0.14% | — | 64.9K | — | — | PN | — | 2021-02-12 | ↗ |
| 32 | James E. Flynn | 64.9K | 0.14% | — | 64.9K | — | — | IN | — | 2021-02-12 | ↗ |
| 33 | BRONCO (BARCLAYS CAYMAN) LIMITED | — | 0.00% | 2.70M | — | 2.70M | — | — | Delaware | 2020-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
55
-223 vs prev Q
New positions
5
Closed positions
225
Increased
23
Reduced
16
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | MACQUARIE MANAGEMENT HOLDINGS, INC. | 688.0K +688.0K (+100.0%) | 24.77B +24.8B (+100.0%) | 1.36% +1.363 pp | 0.04% +0.037 pp | USD36.01 +0.0% | 1 qtrs NEW |
| 2 | BLACKROCK, INC. | 7.71M +137.9K (+1.8%) | 277.53M +39.3M (+16.5%) | 15.26% +0.237 pp | 0.00% +0.001 pp | USD42.38 -15.0% | 6 qtrs — |
| 3 | VANGUARD GROUP INC | 3.58M +68.4K (+1.9%) | 129.06M +18.4M (+16.7%) | 7.10% +0.119 pp | 0.00% +0.000 pp | USD22.03 +63.5% | 45 qtrs — |
| 4 | STATE STREET CORP | 3.16M +356.7K (+12.7%) | 113.93M +25.6M (+29.0%) | 6.27% +0.693 pp | 0.00% +0.001 pp | USD30.69 +17.3% | 40 qtrs — |
| 5 | CONESTOGA CAPITAL ADVISORS, LLC | 2.25M +79.3K (+3.6%) | 81.19M +12.7M (+18.6%) | 4.47% +0.147 pp | 1.37% +0.268 pp | USD39.39 -8.6% | 26 qtrs — |
| 6 | WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC | 2.22M +11.2K (+0.5%) | 80.02M +10.4M (+15.0%) | 4.40% +0.012 pp | 0.22% +0.043 pp | USD39.32 -8.4% | 20 qtrs — |
| 7 | FMR LLC | 2.17M +155.1K (+7.7%) | 78.25M +14.7M (+23.2%) | 4.30% +0.298 pp | 0.00% +0.001 pp | USD45.91 -21.6% | 23 qtrs — |
| 8 | GENEVA CAPITAL MANAGEMENT LLC | 1.83M -119.6K (-6.1%) | 65.78M +4.5M (+7.4%) | 3.62% -0.246 pp | 1.24% +0.185 pp | USD40.80 -11.7% | 10 qtrs — |
| 9 | CONGRESS ASSET MANAGEMENT CO /MA | 1.66M +170.0K (+11.4%) | 59.94M +12.9M (+27.4%) | 3.30% +0.330 pp | 0.42% +0.109 pp | USD46.13 -21.9% | 10 qtrs — |
| 10 | GW&K INVESTMENT MANAGEMENT, LLC | 1.58M +290.8K (+22.5%) | 56.93M +16.3M (+40.2%) | 3.13% +0.570 pp | 0.49% +0.133 pp | USD32.78 +9.9% | 27 qtrs — |
| 11 | BNP PARIBAS ASSET MANAGEMENT HOLDING S.A. | 1.58M +311.7K (+24.6%) | 56.83M +17.0M (+42.6%) | 3.13% +0.611 pp | 0.07% -0.038 pp | USD34.91 +3.2% | 21 qtrs — |
| 12 | GEODE CAPITAL MANAGEMENT, LLC | 1.22M +7.2K (+0.6%) | 44.02M +5.8M (+15.1%) | 2.42% +0.009 pp | 0.00% +0.000 pp | USD24.76 +45.4% | 45 qtrs — |
| 13 | LOOMIS SAYLES & CO L P | 1.06M +51.0K (+5.1%) | 38.05M +6.4M (+20.2%) | 2.09% +0.096 pp | 0.05% +0.008 pp | USD33.68 +6.9% | 17 qtrs — |
| 14 | CHAMPLAIN INVESTMENT PARTNERS, LLC | 1.03M +41.2K (+4.2%) | 37.05M +6.0M (+19.2%) | 2.04% +0.077 pp | 0.38% +0.141 pp | USD49.59 -27.4% | 5 qtrs — |
| 15 | ROYAL BANK OF CANADA | 995.1K -21.4K (-2.1%) | 35.83M +3.8M (+12.0%) | 1.97% -0.047 pp | 0.01% +0.001 pp | USD47.20 -23.7% | 31 qtrs — |
| 16 | BANK OF AMERICA CORP /DE/ | 918.0K +390.4K (+74.0%) | 33.06M +16.5M (+99.1%) | 1.82% +0.771 pp | 0.00% +0.001 pp | USD39.09 -7.9% | 37 qtrs — |
| 17 | BROWN CAPITAL MANAGEMENT LLC | 831.8K -1.1M (-57.4%) | 29.95M -31.4M (-51.2%) | 1.65% -2.226 pp | 2.46% -0.074 pp | USD25.71 +40.1% | 23 qtrs — |
| 18 | DIMENSIONAL FUND ADVISORS LP | 815.6K +17.8K (+2.2%) | 29.37M +4.3M (+17.0%) | 1.62% +0.031 pp | 0.01% +0.001 pp | USD32.71 +10.1% | 27 qtrs — |
| 19 | SOLEUS CAPITAL MANAGEMENT, L.P. | 764.0K +266.0K (+53.4%) | 27.51M +11.8M (+75.6%) | 1.51% +0.525 pp | 1.01% +0.226 pp | USD33.79 +6.6% | 5 qtrs — |
| 20 | MORGAN STANLEY | 697.7K +146.0K (+26.5%) | 25.13M +7.8M (+44.7%) | 1.38% +0.287 pp | 0.00% +0.000 pp | USD34.82 +3.4% | 37 qtrs — |
| 21 | ALLSPRING GLOBAL INVESTMENTS HOLDINGS, LLC | 699.7K -121.8K (-14.8%) | 24.92M -474.8K (-1.9%) | 1.39% -0.245 pp | 0.04% 0.000 pp | USD41.08 -12.3% | 17 qtrs — |
| 22 | SILVERCREST ASSET MANAGEMENT GROUP LLC | 679.8K +480.9K (+241.7%) | 24.48M +18.2M (+291.0%) | 1.35% +0.952 pp | 0.17% +0.127 pp | USD39.92 -9.8% | 8 qtrs — |
| 23 | FEDERATED HERMES, INC. | 642.1K -252.5K (-28.2%) | 23.12M -5.0M (-17.9%) | 1.27% -0.504 pp | 0.04% -0.011 pp | USD40.03 -10.0% | 32 qtrs — |
| 24 | TIMESSQUARE CAPITAL MANAGEMENT, LLC | 631.3K -205.6K (-24.6%) | 22.73M -3.6M (-13.7%) | 1.25% -0.411 pp | 0.34% -0.034 pp | USD45.35 -20.6% | 8 qtrs — |
| 25 | POINT72 ASSET MANAGEMENT, L.P. | 612.9K +612.9K (+100.0%) | 22.07M +22.1M (+100.0%) | 1.21% +1.214 pp | 0.02% +0.025 pp | USD36.01 +0.0% | 1 qtrs NEW |
| 26 | ABRDN PLC | 583.9K +41.0K (+7.6%) | 21.03M +3.9M (+23.1%) | 1.16% +0.079 pp | 0.03% +0.006 pp | USD35.76 +0.7% | 3 qtrs — |
| 27 | NORTHERN TRUST CORP | 529.7K -31.5K (-5.6%) | 19.07M +1.4M (+8.0%) | 1.05% -0.065 pp | 0.00% +0.000 pp | USD15.14 +137.8% | 45 qtrs — |
| 28 | GOLDMAN SACHS GROUP INC | 497.2K +284.3K (+133.6%) | 17.90M +11.2M (+167.3%) | 0.98% +0.562 pp | 0.00% +0.001 pp | USD38.27 -5.9% | 33 qtrs — |
| 29 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 478.3K +28.5K (+6.3%) | 17.22M +3.1M (+21.7%) | 0.95% +0.054 pp | 0.00% +0.000 pp | USD23.69 +52.0% | 31 qtrs — |
| 30 | RAYMOND JAMES FINANCIAL INC | 425.5K +22.6K (+5.6%) | 15.54M +2.9M (+22.6%) | 0.84% +0.043 pp | 0.00% +0.001 pp | USD51.91 -30.6% | 5 qtrs — |
| 31 | SUMMIT CREEK ADVISORS LLC | 422.9K -108.7K (-20.4%) | 15.23M -1.5M (-9.0%) | 0.84% -0.218 pp | 2.40% -0.042 pp | USD26.49 +35.9% | 23 qtrs — |
| 32 | FRONTIER CAPITAL MANAGEMENT CO LLC | 413.7K +7.3K (+1.8%) | 14.90M +2.1M (+16.5%) | 0.82% +0.013 pp | 0.16% +0.043 pp | USD39.07 -7.8% | 9 qtrs — |
| 33 | JPMORGAN CHASE & CO | 336.0K +67.0K (+24.9%) | 12.10M +3.6M (+42.9%) | 0.67% +0.132 pp | 0.00% +0.000 pp | USD39.71 -9.3% | 34 qtrs — |
| 34 | OSTERWEIS CAPITAL MANAGEMENT INC | 323.0K +14.9K (+4.8%) | 11.63M +1.9M (+20.0%) | 0.64% +0.028 pp | 0.49% +0.055 pp | USD39.51 -8.9% | 3 qtrs — |
| 35 | INVESCO LTD. | 291.0K -453.9K (-60.9%) | 10.48M -13.0M (-55.3%) | 0.58% -0.903 pp | 0.00% -0.002 pp | USD43.10 -16.5% | 31 qtrs — |
| 36 | BANK OF NEW YORK MELLON CORP | 284.4K -9.1K (-3.1%) | 10.24M +1.0M (+10.9%) | 0.56% -0.019 pp | 0.00% +0.000 pp | USD37.24 -3.3% | 40 qtrs — |
| 37 | D. E. SHAW & CO., INC. | 280.3K +37.0K (+15.2%) | 10.09M +2.4M (+31.8%) | 0.56% +0.072 pp | 0.01% +0.001 pp | USD36.55 -1.5% | 16 qtrs — |
| 38 | WELLINGTON MANAGEMENT GROUP LLP | 280.2K -7.9K (-2.8%) | 10.09M +1.0M (+11.3%) | 0.56% -0.017 pp | 0.00% +0.000 pp | USD49.39 -27.1% | 8 qtrs — |
| 39 | WOODLINE PARTNERS LP | 265.4K -1.8K (-0.7%) | 9.56M +1.1M (+13.6%) | 0.53% -0.005 pp | 0.04% -0.003 pp | USD31.47 +14.4% | 2 qtrs — |
| 40 | AMERIPRISE FINANCIAL INC | 248.3K -5.7K (-2.3%) | 8.94M +946.6K (+11.8%) | 0.49% -0.013 pp | 0.00% +0.000 pp | USD35.05 +2.7% | 25 qtrs — |
| 41 | PRINCIPAL FINANCIAL GROUP INC | 241.8K -2.2K (-0.9%) | 8.71M +1.0M (+13.4%) | 0.48% -0.006 pp | 0.00% +0.001 pp | USD53.33 -32.5% | 21 qtrs — |
| 42 | SEI INVESTMENTS CO | 232.2K +26.0K (+12.6%) | 8.36M +1.9M (+28.8%) | 0.46% +0.050 pp | 0.01% +0.001 pp | USD41.56 -13.4% | 31 qtrs — |
| 43 | DIVISADERO STREET CAPITAL MANAGEMENT, LP | 225.0K +225.0K (+100.0%) | 8.10M +8.1M (+100.0%) | 0.45% +0.446 pp | 0.38% +0.379 pp | USD36.01 +0.0% | 1 qtrs NEW |
| 44 | COMERICA BANK | 222.2K -20.0K (-8.3%) | 8.00M +378.5K (+5.0%) | 0.44% -0.041 pp | 0.03% +0.003 pp | USD36.67 -1.8% | 10 qtrs — |
| 45 | ENVESTNET ASSET MANAGEMENT INC | 203.6K -22.1K (-9.8%) | 7.33M +228.3K (+3.2%) | 0.40% -0.045 pp | 0.00% +0.000 pp | USD40.96 -12.1% | 20 qtrs — |
| 46 | PEREGRINE CAPITAL MANAGEMENT LLC | 203.2K -2.7K (-1.3%) | 7.32M +836.6K (+12.9%) | 0.40% -0.006 pp | 0.22% +0.029 pp | USD42.55 -15.4% | 3 qtrs — |
| 47 | FISHER ASSET MANAGEMENT, LLC | 187.6K +18.0K (+10.6%) | 6.76M +1.4M (+26.6%) | 0.37% +0.035 pp | 0.00% +0.000 pp | USD42.76 -15.8% | 22 qtrs — |
| 48 | THRIVENT FINANCIAL FOR LUTHERANS | 183.7K -16.1K (-8.1%) | 6.62M +328.0K (+5.2%) | 0.36% -0.033 pp | 0.01% -0.001 pp | USD31.64 +13.8% | 20 qtrs — |
| 49 | PUBLIC SECTOR PENSION INVESTMENT BOARD | 174.9K -21.9K (-11.1%) | 6.30M +103.5K (+1.7%) | 0.35% -0.044 pp | 0.02% -0.002 pp | USD45.04 -20.0% | 20 qtrs — |
| 50 | UBS GROUP AG | 167.5K -18.0K (-9.7%) | 6.03M +195.1K (+3.3%) | 0.33% -0.037 pp | 0.00% +0.000 pp | USD44.66 -19.4% | 32 qtrs — |
| 51 | MUTUAL OF AMERICA CAPITAL MANAGEMENT LLC | 161.9K +8.3K (+5.4%) | 5.83M +994.9K (+20.6%) | 0.32% +0.016 pp | 0.06% +0.010 pp | USD21.22 +69.7% | 31 qtrs — |
| 52 | KOPP FAMILY OFFICE, LLC | 161.7K -11.0K (-6.4%) | 5.82M +387.7K (+7.1%) | 0.32% -0.023 pp | 3.72% +0.179 pp | USD13.27 +171.4% | 25 qtrs — |
| 53 | BARCLAYS PLC | 157.6K +46.1K (+41.3%) | 5.68M +964.0K (+20.5%) | 0.31% +0.091 pp | 0.00% +0.000 pp | USD39.40 -8.6% | 34 qtrs — |
| 54 | TREXQUANT INVESTMENT LP | 154.6K +105.7K (+216.4%) | 5.57M +4.0M (+262.0%) | 0.31% +0.209 pp | 0.05% +0.034 pp | USD34.57 +4.2% | 12 qtrs — |
| 55 | SEGALL BRYANT & HAMILL, LLC | 150.5K +13.2K (+9.6%) | 5.42M +1.1M (+25.4%) | 0.30% +0.026 pp | 0.07% +0.016 pp | USD39.09 -7.9% | 10 qtrs — |
| 56 | RHUMBLINE ADVISERS | 139.6K -8.7K (-5.9%) | 5.03M +359.6K (+7.7%) | 0.28% -0.018 pp | 0.00% +0.000 pp | USD34.31 +5.0% | 31 qtrs — |
| 57 | ADVISOR GROUP HOLDINGS, INC. | 137.2K -55.3K (-28.7%) | 4.94M -1.1M (-18.5%) | 0.27% -0.110 pp | 0.01% -0.001 pp | USD31.41 +14.6% | 24 qtrs — |
| 58 | SUSQUEHANNA PORTFOLIO STRATEGIES, LLC | 135.1K +40.9K (+43.5%) | 4.86M +1.9M (+64.2%) | 0.27% +0.081 pp | 0.08% +0.028 pp | USD35.72 +0.8% | 3 qtrs — |
| 59 | RUSSELL INVESTMENTS GROUP, LTD. | 134.4K -41.7K (-23.7%) | 4.84M -700.6K (-12.6%) | 0.27% -0.083 pp | 0.01% -0.001 pp | USD35.51 +1.4% | 33 qtrs — |
| 60 | RICE HALL JAMES & ASSOCIATES, LLC | 130.0K +120.0K (+1,205.4%) | 4.68M +4.4M (+1,393.8%) | 0.26% +0.238 pp | 0.26% +0.241 pp | USD35.66 +1.0% | 2 qtrs — |
| 61 | LEGAL & GENERAL GROUP PLC | 125.9K -9.3K (-6.9%) | 4.53M +279.7K (+6.6%) | 0.25% -0.019 pp | 0.00% +0.000 pp | USD49.17 -26.8% | 31 qtrs — |
| 62 | RHENMAN & PARTNERS ASSET MANAGEMENT AB | 117.0K +— (+0.0%) | 4.21M +531.2K (+14.4%) | 0.23% -0.001 pp | 0.39% -0.014 pp | USD36.96 -2.6% | 3 qtrs — |
| 63 | KORNITZER CAPITAL MANAGEMENT INC /KS | 114.8K +110.0 (+0.1%) | 4.13M +524.6K (+14.5%) | 0.23% 0.000 pp | 0.09% +0.013 pp | USD43.51 -17.2% | 5 qtrs — |
| 64 | WELLS FARGO & COMPANY/MN | 112.9K +17.9K (+18.8%) | 4.07M +1.1M (+36.0%) | 0.22% +0.035 pp | 0.00% +0.000 pp | USD32.52 +10.7% | 35 qtrs — |
| 65 | FIRST WASHINGTON CORP | 109.8K -1.3K (-1.2%) | 3.96M +457.3K (+13.1%) | 0.22% -0.003 pp | 1.02% +0.087 pp | USD24.33 +48.0% | 35 qtrs — |
| 66 | NUVEEN, LLC | 102.3K -3.4K (-3.2%) | 3.68M +357.9K (+10.8%) | 0.20% -0.007 pp | 0.00% +0.000 pp | USD44.62 -19.3% | 4 qtrs — |
| 67 | CENTERBOOK PARTNERS LP | 102.2K -82.7K (-44.7%) | 3.68M -2.1M (-36.8%) | 0.20% -0.165 pp | 0.18% -0.108 pp | USD35.78 +0.6% | 8 qtrs — |
| 68 | LPL FINANCIAL LLC | 102.0K +222.0 (+0.2%) | 3.67M +470.2K (+14.7%) | 0.20% +0.000 pp | 0.00% +0.000 pp | USD44.40 -18.9% | 20 qtrs — |
| 69 | SWISS NATIONAL BANK | 99.5K +1.9K (+1.9%) | 3.58M +511.5K (+16.7%) | 0.20% +0.003 pp | 0.00% +0.000 pp | USD24.01 +50.0% | 29 qtrs — |
| 70 | UBS ASSET MANAGEMENT AMERICAS INC | 96.3K +2.7K (+2.9%) | 3.47M +521.4K (+17.7%) | 0.19% +0.005 pp | 0.00% +0.000 pp | USD41.08 -12.3% | 29 qtrs — |
| 71 | MARSHALL WACE, LLP | 91.2K +91.2K (+100.0%) | 3.28M +3.3M (+100.0%) | 0.18% +0.181 pp | 0.00% +0.003 pp | USD36.01 +0.0% | 1 qtrs NEW |
| 72 | SIT INVESTMENT ASSOCIATES INC | 80.2K -3.0K (-3.6%) | 2.89M +269.0K (+10.3%) | 0.16% -0.006 pp | 0.06% +0.004 pp | USD41.77 -13.8% | 10 qtrs — |
| 73 | BNP PARIBAS ARBITRAGE, SNC | 78.5K +20.4K (+35.1%) | 2.83M +998.1K (+54.6%) | 0.16% +0.040 pp | 0.00% +0.000 pp | USD36.98 -2.6% | 31 qtrs — |
| 74 | VICTORY CAPITAL MANAGEMENT INC | 78.2K -143.9K (-64.8%) | 2.82M -4.2M (-59.7%) | 0.15% -0.286 pp | 0.00% -0.003 pp | USD48.92 -26.4% | 20 qtrs — |
| 75 | RAFFERTY ASSET MANAGEMENT, LLC | 75.6K +6.4K (+9.3%) | 2.72M +545.2K (+25.0%) | 0.15% +0.012 pp | 0.01% +0.002 pp | USD38.45 -6.3% | 28 qtrs — |
| 76 | GRANITE INVESTMENT PARTNERS, LLC | 72.2K +72.2K (+100.0%) | 2.60M +2.6M (+100.0%) | 0.14% +0.143 pp | 0.15% +0.154 pp | USD36.01 +0.0% | 1 qtrs NEW |
| 77 | QUBE RESEARCH & TECHNOLOGIES LTD | 68.0K -92.4K (-57.6%) | 2.45M -2.6M (-51.5%) | 0.13% -0.184 pp | 0.00% -0.003 pp | USD43.84 -17.9% | 10 qtrs — |
| 78 | UNIVERSAL- BETEILIGUNGS- UND SERVICEGESELLSCHAFT MBH | 61.2K +13.2K (+27.5%) | 2.20M +692.6K (+45.9%) | 0.12% +0.026 pp | 0.00% +0.001 pp | USD42.23 -14.7% | 4 qtrs — |
| 79 | ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/ | 60.1K -7.8K (-11.5%) | 2.16M +27.2K (+1.3%) | 0.12% -0.016 pp | 0.10% -0.006 pp | USD41.98 -14.2% | 4 qtrs — |
| 80 | ALLIANCEBERNSTEIN L.P. | 58.6K +6.3K (+12.0%) | 2.11M +463.4K (+28.1%) | 0.12% +0.012 pp | 0.00% +0.000 pp | USD31.57 +14.1% | 31 qtrs — |
| 81 | CERITY PARTNERS LLC | 58.6K +4.9K (+9.1%) | 2.11M +419.0K (+24.8%) | 0.12% +0.009 pp | 0.00% +0.000 pp | USD45.90 -21.5% | 8 qtrs — |
| 82 | STATE OF WISCONSIN INVESTMENT BOARD | 53.0K +23.9K (+82.3%) | 1.91M +993.0K (+108.6%) | 0.10% +0.047 pp | 0.00% +0.002 pp | USD34.16 +5.4% | 30 qtrs — |
| 83 | DEUTSCHE BANK AG\ | 51.5K +2.2K (+4.5%) | 1.85M +303.0K (+19.5%) | 0.10% +0.004 pp | 0.00% +0.000 pp | USD40.33 -10.7% | 37 qtrs — |
| 84 | SQUAREPOINT OPS LLC | 50.8K -23.2K (-31.4%) | 1.83M -500.4K (-21.5%) | 0.10% -0.046 pp | 0.00% 0.000 pp | USD31.47 +14.4% | 2 qtrs — |
| 85 | MADISON ASSET MANAGEMENT, LLC | 50.5K +50.5K (+100.0%) | 1.82M +1.8M (+100.0%) | 0.10% +0.100 pp | 0.02% +0.021 pp | USD36.01 +0.0% | 1 qtrs NEW |
| 86 | CITADEL ADVISORS LLC | 50.1K -131.1K (-72.4%) | 1.80M -3.9M (-68.4%) | 0.10% -0.261 pp | 0.00% -0.001 pp | USD34.13 +5.5% | 37 qtrs — |
| 87 | GLOBAL ALPHA CAPITAL MANAGEMENT LTD. | 50.1K +15.5K (+44.9%) | 1.80M +715.0K (+65.7%) | 0.10% +0.031 pp | 0.11% +0.048 pp | USD41.79 -13.8% | 7 qtrs — |
| 88 | PRICE T ROWE ASSOCIATES INC /MD/ | 49.8K +5.7K (+13.0%) | 1.80M +407.0K (+29.3%) | 0.10% +0.011 pp | 0.00% +0.000 pp | USD43.45 -17.1% | 20 qtrs — |
| 89 | NEW YORK STATE TEACHERS RETIREMENT SYSTEM | 49.4K +— (+0.0%) | 1.78M +224.0K (+14.4%) | 0.10% 0.000 pp | 0.00% +0.000 pp | USD51.36 -29.9% | 20 qtrs — |
| 90 | STIFEL FINANCIAL CORP | 49.3K +1.6K (+3.3%) | 1.78M +274.1K (+18.2%) | 0.10% +0.003 pp | 0.00% +0.000 pp | USD38.00 -5.2% | 22 qtrs — |
| 91 | VOLORIDGE INVESTMENT MANAGEMENT, LLC | 48.7K -167.4K (-77.5%) | 1.75M -5.0M (-74.2%) | 0.10% -0.333 pp | 0.01% -0.017 pp | USD35.91 +0.3% | 5 qtrs — |
| 92 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | 48.5K -44.0 (-0.1%) | 1.75M +218.7K (+14.3%) | 0.10% 0.000 pp | 0.00% +0.000 pp | USD15.82 +127.6% | 31 qtrs — |
| 93 | PRUDENTIAL FINANCIAL INC | 47.7K -3.3K (-6.5%) | 1.72M +112.4K (+7.0%) | 0.09% -0.007 pp | 0.00% +0.000 pp | USD44.88 -19.8% | 20 qtrs — |
| 94 | — | 45.7K -32.0K (-41.2%) | 1.65M -799.6K (-32.7%) | 0.09% -0.064 pp | 0.57% -0.147 pp | USD31.47 +14.4% | 2 qtrs — |
| 95 | GREAT WEST LIFE ASSURANCE CO /CAN/ | 44.0K -12.0K (-21.4%) | 1.58M -196.0K (-11.0%) | 0.09% -0.024 pp | 0.00% +0.000 pp | USD43.87 -17.9% | 29 qtrs — |
| 96 | LINDEN THOMAS ADVISORY SERVICES, LLC | 43.3K -512.0 (-1.2%) | 1.56M +180.4K (+13.1%) | 0.09% -0.001 pp | 0.16% +0.019 pp | USD38.38 -6.2% | 11 qtrs — |
| 97 | ALPS ADVISORS INC | 41.5K +18.7K (+81.7%) | 1.50M +776.0K (+107.9%) | 0.08% +0.037 pp | 0.01% +0.005 pp | USD33.49 +7.5% | 15 qtrs — |
| 98 | STERLING CAPITAL MANAGEMENT LLC | 40.4K +40.2K (+32,977.0%) | 1.45M +1.4M (+37,752.3%) | 0.08% +0.080 pp | 0.02% +0.024 pp | USD36.03 -0.1% | 6 qtrs — |
| 99 | FRANKLIN RESOURCES INC | 40.0K +219.0 (+0.6%) | 1.44M +188.6K (+15.1%) | 0.08% +0.000 pp | 0.00% +0.000 pp | USD43.61 -17.4% | 11 qtrs — |
Ownership breakdown by holder
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
26.00
Bullish
Ratio by volume
3.00
Bullish
Buys
26
Sells
1
Shares acquired
112.5K
Shares disposed
3.5K
Cash buys
—
Cash sales
1.00
Net activity
+109,072
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-29 | ZERBE ROBERT L MD | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | D | ↗ |
| 2026-04-29 | Wotton Paul K | Director | M-Exempt | A | Common Stock | 3,200 | 0.00 | — | 28,802 | D | ↗ |
| 2026-04-29 | WRIGHT LISA | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | D | ↗ |
| 2026-04-29 | Rubino Alan L | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | D | ↗ |
| 2026-04-29 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Common Stock | 3,200 | 0.00 | — | 18,300 | D | ↗ |
| 2026-04-29 | Hagen Heidi | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | D | ↗ |
| 2026-04-02 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 3,472 | 10.95 | 38.0K | 79,028 | D | ↗ |
| 2026-03-25 | Rubino Alan L | Director | M-Exempt | A | Stock Option (Right to Buy) | 15,000 | 2.76 | 41.4K | 0 | D | ↗ |
| 2026-03-23 | Hagen Heidi | Director | S-Sale | D | Common Stock | 15,000 | 32.41 | 486.2K | 31,850 | D | ↗ |
| 2026-03-02 | Halpin Michael | Officer | S-Sale | D | Common Stock | 10,305 | 35.30 | 363.8K | 16,080 | D | ↗ |
| 2026-03-02 | Flynn Sean C. | Officer | M-Exempt | A | Stock Option (Right to Buy) | 15,000 | 16.25 | 243.8K | 85,000 | D | ↗ |
| 2026-02-24 | SIEGAL JONATHAN | Officer | M-Exempt | A | Restricted Stock Unit | 1,540 | 0.00 | — | 4,620 | D | ↗ |
| 2026-02-24 | Mara Joseph Anthony Jr | Officer | M-Exempt | A | Restricted Stock Unit | 4,625 | 0.00 | — | 13,875 | D | ↗ |
| 2026-02-24 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 3,150 | 0.00 | — | 74,527 | D | ↗ |
| 2026-02-24 | Halpin Michael | Officer | M-Exempt | A | Common Stock | 5,250 | 0.00 | — | 28,871 | D | ↗ |
| 2026-02-24 | Flynn Sean C. | Officer | M-Exempt | A | Restricted Stock Unit | 3,500 | 0.00 | — | 10,500 | D | ↗ |
| 2026-02-24 | Colangelo Dominick | Director / Officer | M-Exempt | A | Restricted Stock Unit | 18,250 | 0.00 | — | 36,500 | D | ↗ |
| 2026-02-19 | SIEGAL JONATHAN | Officer | A-Award | A | Restricted Stock Unit | 6,160 | 0.00 | — | 6,160 | D | ↗ |
| 2026-02-19 | Mara Joseph Anthony Jr | Officer | A-Award | A | Restricted Stock Unit | 18,500 | 0.00 | — | 18,500 | D | ↗ |
| 2026-02-19 | Hopper Jonathan Mark | Officer | A-Award | A | Restricted Stock Unit | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2026-02-19 | Halpin Michael | Officer | A-Award | A | Restricted Stock Unit | 21,000 | 0.00 | — | 21,000 | D | ↗ |
| 2026-02-19 | Flynn Sean C. | Officer | A-Award | A | Restricted Stock Unit | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2026-02-19 | Colangelo Dominick | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 182,500 | 38.17 | 6.97M | 182,500 | D | ↗ |
| 2026-02-18 | SIEGAL JONATHAN | Officer | M-Exempt | A | Restricted Stock Unit | 420 | 0.00 | — | 0 | D | ↗ |
| 2026-02-18 | Mara Joseph Anthony Jr | Officer | M-Exempt | A | Restricted Stock Unit | 4,625 | 0.00 | — | 4,625 | D | ↗ |
| 2026-02-18 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 69,684 | D | ↗ |
| 2026-02-18 | Halpin Michael | Officer | M-Exempt | A | Restricted Stock Unit | 5,250 | 0.00 | — | 5,250 | D | ↗ |
| 2026-02-18 | Flynn Sean C. | Officer | M-Exempt | A | Common Stock | 3,000 | 0.00 | — | 4,262 | D | ↗ |
| 2026-02-18 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 11,700 | 0.00 | — | 290,427 | D | ↗ |
| 2026-02-11 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Stock Option (Right to Buy) | 7,000 | 2.63 | 18.4K | 3,500 | D | ↗ |
| 2026-01-07 | Halpin Michael | Officer | S-Sale | D | Common Stock | 10,000 | 40.48 | 404.8K | 16,080 | D | ↗ |
| 2025-12-31 | SIEGAL JONATHAN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-31 | Mara Joseph Anthony Jr | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-31 | Hopper Jonathan Mark | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-31 | Flynn Sean C. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-31 | Colangelo Dominick | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2025-12-03 | Wotton Paul K | Director | S-Sale | D | Common Stock | 2,500 | 37.83 | 94.6K | 25,602 | D | ↗ |
| 2025-12-02 | Wotton Paul K | Director | S-Sale | D | Common Stock | 2,500 | 37.97 | 94.9K | 28,102 | D | ↗ |
| 2025-12-02 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 1,652 | 18.00 | 29.7K | 68,214 | D | ↗ |
| 2025-11-11 | Halpin Michael | Officer | M-Exempt | A | Stock Option (Right to Buy) | 2,642 | 16.66 | 44.0K | 56,250 | D | ↗ |
| 2025-11-10 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Common Stock | 7,000 | 2.63 | 18.4K | 22,100 | D | ↗ |
| 2025-11-06 | Halpin Michael | Officer | S-Sale | D | Common Stock | 7,358 | 40.47 | 297.8K | 15,932 | D | ↗ |
| 2025-09-30 | SIEGAL JONATHAN | Officer | M-Exempt | A | Common Stock | 938 | 0.00 | — | 2,440 | D | ↗ |
| 2025-09-02 | Hopper Jonathan Mark | Officer | M-Exempt | A | Stock Option (Right to Buy) | 10,000 | 18.00 | 180.0K | 8,750 | D | ↗ |
| 2025-08-06 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Common Stock | 7,000 | 2.76 | 19.3K | 22,100 | D | ↗ |
| 2025-07-22 | Mahoney Karen | Officer | M-Exempt | A | Restricted Stock Unit | 2,625 | 0.00 | — | 7,875 | D | ↗ |
| 2025-06-02 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 10,000 | 18.00 | 180.0K | 76,237 | D | ↗ |
| 2025-05-15 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 14,063 | 2.65 | 37.3K | 0 | D | ↗ |
| 2025-05-14 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 14,062 | 2.65 | 37.3K | 274,416 | D | ↗ |
| 2025-05-07 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Common Stock | 7,000 | 2.76 | 19.3K | 22,100 | D | ↗ |
| 2025-04-30 | ZERBE ROBERT L MD | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | D | ↗ |
| 2025-04-30 | Wotton Paul K | Director | A-Award | A | Stock Option (Right to Buy) | 8,000 | 38.02 | 304.2K | 8,000 | D | ↗ |
| 2025-04-30 | WRIGHT LISA | Director | A-Award | A | Restricted Stock Unit | 3,200 | 0.00 | — | 3,200 | D | ↗ |
| 2025-04-30 | Rubino Alan L | Director | A-Award | A | Stock Option (Right to Buy) | 8,000 | 38.02 | 304.2K | 8,000 | D | ↗ |
| 2025-04-30 | Mahoney Karen | Officer | A-Award | A | Restricted Stock Unit | 5,175 | 0.00 | — | 5,175 | D | ↗ |
| 2025-04-30 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | D | ↗ |
| 2025-04-30 | Hagen Heidi | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | D | ↗ |
| 2025-04-10 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 24,850 | 41.89 | 1.04M | 260,354 | D | ↗ |
| 2025-04-09 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 24,850 | 41.11 | 1.02M | 260,354 | D | ↗ |
| 2025-03-13 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 26,592 | 1.95 | 51.9K | 286,589 | D | ↗ |
| 2025-03-12 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 26,591 | 1.95 | 51.9K | 286,588 | D | ↗ |
| 2025-03-03 | Mara Joseph Anthony Jr | Officer | S-Sale | D | Common Stock | 9,000 | 49.53 | 445.8K | 13,967 | D | ↗ |
| 2025-03-03 | Hopper Jonathan Mark | Officer | M-Exempt | A | Stock Option (Right to Buy) | 10,000 | 18.00 | 180.0K | 28,750 | D | ↗ |
| 2025-03-03 | Halpin Michael | Officer | S-Sale | D | Common Stock | 10,000 | 49.52 | 495.2K | 15,539 | D | ↗ |
| 2025-03-03 | Hagen Heidi | Director | S-Sale | D | Common Stock | 9,000 | 49.53 | 445.8K | 28,650 | D | ↗ |
| 2025-02-25 | SIEGAL JONATHAN | Officer | S-Sale | D | Common Stock | 1,137 | 52.07 | 59.2K | 1,206 | D | ↗ |
| 2025-02-25 | Flynn Sean C. | Officer | S-Sale | D | Common Stock | 1,669 | 52.07 | 86.9K | 756 | D | ↗ |
| 2025-02-24 | SIEGAL JONATHAN | Officer | F-InKind | D | Common Stock | 738 | 52.33 | 38.6K | 2,343 | D | ↗ |
| 2025-02-24 | Mara Joseph Anthony Jr | Officer | M-Exempt | A | Common Stock | 4,625 | 0.00 | — | 24,325 | D | ↗ |
| 2025-02-24 | Hopper Jonathan Mark | Officer | M-Exempt | A | Restricted Stock Unit | 1,500 | 0.00 | — | 9,000 | D | ↗ |
| 2025-02-24 | Halpin Michael | Officer | F-InKind | D | Common Stock | 2,486 | 52.33 | 130.1K | 15,539 | D | ↗ |
| 2025-02-24 | Flynn Sean C. | Officer | F-InKind | D | Common Stock | 1,331 | 52.33 | 69.7K | 2,425 | D | ↗ |
| 2025-02-24 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 18,250 | 0.00 | — | 268,456 | D | ↗ |
| 2025-02-20 | SIEGAL JONATHAN | Officer | A-Award | A | Stock Option (Right to Buy) | 6,600 | 54.31 | 358.4K | 6,600 | D | ↗ |
| 2025-02-20 | Mara Joseph Anthony Jr | Officer | A-Award | A | Restricted Stock Unit | 18,500 | 0.00 | — | 18,500 | D | ↗ |
| 2025-02-20 | Mahoney Karen | Officer | A-Award | A | Stock Option (Right to Buy) | 12,938 | 54.31 | 702.7K | 12,938 | D | ↗ |
| 2025-02-20 | Hopper Jonathan Mark | Officer | A-Award | A | Restricted Stock Unit | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2025-02-20 | Halpin Michael | Officer | A-Award | A | Restricted Stock Unit | 21,000 | 0.00 | — | 21,000 | D | ↗ |
| 2025-02-20 | Flynn Sean C. | Officer | A-Award | A | Restricted Stock Unit | 14,000 | 0.00 | — | 14,000 | D | ↗ |
| 2025-02-20 | Colangelo Dominick | Director / Officer | A-Award | A | Restricted Stock Unit | 73,000 | 0.00 | — | 73,000 | D | ↗ |
| 2025-02-19 | SIEGAL JONATHAN | Officer | S-Sale | D | Common Stock | 1,710 | 56.72 | 97.0K | 1,206 | D | ↗ |
| 2025-02-19 | Mahoney Karen | Officer | — | — | Restricted Stock Unit | 10,500 | 0.00 | — | 0 | D | ↗ |
| 2025-02-19 | Hopper Jonathan Mark | Officer | M-Exempt | A | Restricted Stock Unit | 1,750 | 0.00 | — | 0 | D | ↗ |
| 2025-02-19 | Halpin Michael | Officer | M-Exempt | A | Common Stock | 2,813 | 0.00 | — | 14,107 | D | ↗ |
| 2025-02-19 | Flynn Sean C. | Officer | M-Exempt | A | Restricted Stock Unit | 1,750 | 0.00 | — | 0 | D | ↗ |
| 2025-02-19 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 8,938 | 0.00 | — | 254,402 | D | ↗ |
| 2025-02-18 | SIEGAL JONATHAN | Officer | F-InKind | D | Common Stock | 1,044 | 57.28 | 59.8K | 2,662 | D | ↗ |
| 2025-02-18 | Mara Joseph Anthony Jr | Officer | M-Exempt | A | Restricted Stock Unit | 2,754 | 0.00 | — | 2,755 | D | ↗ |
| 2025-02-18 | Hopper Jonathan Mark | Officer | F-InKind | D | Common Stock | 985 | 57.28 | 56.4K | 62,840 | D | ↗ |
| 2025-02-18 | Halpin Michael | Officer | M-Exempt | A | Common Stock | 3,825 | 0.00 | — | 13,106 | D | ↗ |
| 2025-02-18 | Flynn Sean C. | Officer | M-Exempt | A | Common Stock | 2,325 | 0.00 | — | 4,650 | D | ↗ |
| 2025-02-18 | Colangelo Dominick | Director / Officer | M-Exempt | A | Restricted Stock Unit | 18,250 | 0.00 | — | 36,500 | D | ↗ |
| 2025-02-12 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Common Stock | 1,000 | 2.76 | 2.8K | 12,900 | D | ↗ |
| 2025-02-07 | Rubino Alan L | Director | M-Exempt | A | Common Stock | 15,000 | 3.74 | 56.1K | 42,794 | D | ↗ |
| 2025-02-05 | ZERBE ROBERT L MD | Director | M-Exempt | A | Common Stock | 2,500 | 13.05 | 32.6K | 29,095 | D | ↗ |
| 2025-02-05 | SIEGAL JONATHAN | Officer | M-Exempt | A | Common Stock | 1,092 | 48.80 | 53.3K | 2,298 | D | ↗ |
| 2025-01-28 | SIEGAL JONATHAN | Officer | S-Sale | D | Common Stock | 3,908 | 61.99 | 242.3K | 1,206 | D | ↗ |
| 2024-12-31 | Mara Joseph Anthony Jr | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Hopper Jonathan Mark | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Halpin Michael | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-31 | Flynn Sean C. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-04 | Wotton Paul K | Director | S-Sale | D | Common Stock | 2,600 | 58.72 | 152.7K | 27,402 | D | ↗ |
| 2024-12-02 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 10,000 | 16.66 | 166.6K | 68,371 | D | ↗ |
| 2024-11-22 | ZERBE ROBERT L MD | Director | M-Exempt | A | Common Stock | 2,500 | 13.05 | 32.6K | 29,095 | D | ↗ |
| 2024-11-14 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 17,500 | 3.02 | 52.9K | 238,437 | D | ↗ |
| 2024-11-13 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Stock Option (Right to Buy) | 7,000 | 3.74 | 26.2K | 6,000 | D | ↗ |
| 2024-11-13 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 55.57 | 972.5K | 220,937 | D | ↗ |
| 2024-11-12 | ZERBE ROBERT L MD | Director | M-Exempt | A | Common Stock | 2,500 | 13.05 | 32.6K | 29,095 | D | ↗ |
| 2024-11-11 | ZERBE ROBERT L MD | Director | S-Sale | D | Common Stock | 2,500 | 55.00 | 137.5K | 26,595 | D | ↗ |
| 2024-10-17 | Hagen Heidi | Director | M-Exempt | A | Stock Option (Right to Buy) | 4,000 | 3.74 | 15.0K | 0 | D | ↗ |
| 2024-10-17 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 17,500 | 3.02 | 52.9K | 35,000 | D | ↗ |
| 2024-10-16 | GILMAN STEVEN C | Director | M-Exempt | A | Common Stock | 5,833 | 13.05 | 76.1K | 16,833 | D | ↗ |
| 2024-10-16 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 41.38 | 724.2K | 220,937 | D | ↗ |
| 2024-10-02 | GILMAN STEVEN C | Director | M-Exempt | A | Common Stock | 5,833 | 13.05 | 76.1K | 16,833 | D | ↗ |
| 2024-10-01 | SIEGAL JONATHAN | Officer | S-Sale | D | Common Stock | 568 | 41.90 | 23.8K | 1,124 | D | ↗ |
| 2024-09-30 | SIEGAL JONATHAN | Officer | M-Exempt | A | Common Stock | 937 | 0.00 | — | 2,061 | D | ↗ |
| 2024-09-18 | GILMAN STEVEN C | Director | S-Sale | D | Common Stock | 5,834 | 45.54 | 265.7K | 11,000 | D | ↗ |
| 2024-09-12 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 17,500 | 3.02 | 52.9K | 238,437 | — | ↗ |
| 2024-09-11 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 43.37 | 759.0K | 220,937 | — | ↗ |
| 2024-09-04 | GILMAN STEVEN C | Director | M-Exempt | A | Common Stock | 5,000 | 3.74 | 18.7K | 16,000 | — | ↗ |
| 2024-09-03 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 10,000 | 10.95 | 109.5K | 68,229 | — | ↗ |
| 2024-08-15 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 17,500 | 3.02 | 52.9K | 238,437 | — | ↗ |
| 2024-08-14 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 17,500 | 3.02 | 52.9K | 122,500 | — | ↗ |
| 2024-08-07 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Common Stock | 5,000 | 3.74 | 18.7K | 16,900 | — | ↗ |
| 2024-07-18 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 17,500 | 3.02 | 52.9K | 238,437 | — | ↗ |
| 2024-07-17 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 51.55 | 902.1K | 220,937 | — | ↗ |
| 2024-07-16 | Flynn Sean C. | Officer | M-Exempt | A | Common Stock | 15,000 | 16.25 | 243.8K | 15,707 | — | ↗ |
| 2024-07-12 | Mara Joseph Anthony Jr | Officer | S-Sale | D | Common Stock | 5,000 | 50.00 | 250.0K | 14,436 | — | ↗ |
| 2024-07-05 | SIEGAL JONATHAN | Officer | S-Sale | D | Common Stock | 545 | 45.00 | 24.5K | 1,033 | — | ↗ |
| 2024-06-24 | Flynn Sean C. | Officer | M-Exempt | A | Stock Option (Right to Buy) | 1,474 | 16.25 | 24.0K | 115,000 | — | ↗ |
| 2024-06-21 | Flynn Sean C. | Officer | M-Exempt | A | Stock Option (Right to Buy) | 6,772 | 16.25 | 110.0K | 116,474 | — | ↗ |
| 2024-06-20 | Flynn Sean C. | Officer | M-Exempt | A | Stock Option (Right to Buy) | 6,754 | 16.25 | 109.8K | 123,246 | — | ↗ |
| 2024-06-13 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 43.10 | 754.3K | 220,752 | — | ↗ |
| 2024-06-12 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 44.12 | 772.1K | 220,752 | — | ↗ |
| 2024-06-03 | WRIGHT LISA | Director | M-Exempt | A | Common Stock | 434 | 0.00 | — | 9,451 | — | ↗ |
| 2024-05-20 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 10,000 | 10.95 | 109.5K | 68,116 | — | ↗ |
| 2024-05-17 | Halpin Michael | Officer | M-Exempt | A | Common Stock | 3,132 | 7.20 | 22.6K | 6,284 | — | ↗ |
| 2024-05-16 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 47.85 | 837.4K | 220,752 | — | ↗ |
| 2024-05-15 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 17,500 | 3.02 | 52.9K | 227,500 | — | ↗ |
| 2024-05-01 | ZERBE ROBERT L MD | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | — | ↗ |
| 2024-05-01 | Wotton Paul K | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | — | ↗ |
| 2024-05-01 | WRIGHT LISA | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | — | ↗ |
| 2024-05-01 | Rubino Alan L | Director | M-Exempt | A | Common Stock | 3,200 | 0.00 | — | 23,794 | — | ↗ |
| 2024-05-01 | MCLAUGHLIN KEVIN F | Director | M-Exempt | A | Common Stock | 3,200 | 0.00 | — | 11,900 | — | ↗ |
| 2024-05-01 | Hagen Heidi | Director | M-Exempt | A | Restricted Stock Unit | 3,200 | 0.00 | — | 0 | — | ↗ |
| 2024-05-01 | GILMAN STEVEN C | Director | M-Exempt | A | Common Stock | 3,200 | 0.00 | — | 11,000 | — | ↗ |
| 2024-04-30 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 5,555 | 18.00 | 100.0K | 219,445 | — | ↗ |
| 2024-04-18 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 17,500 | 3.02 | 52.9K | 245,000 | — | ↗ |
| 2024-04-17 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 17,500 | 3.02 | 52.9K | 262,500 | — | ↗ |
| 2024-04-09 | Rubino Alan L | Director | M-Exempt | A | Common Stock | 3,000 | 4.12 | 12.4K | 20,594 | — | ↗ |
| 2024-03-27 | ZERBE ROBERT L MD | Director | M-Exempt | A | Common Stock | 3,278 | 3.74 | 12.3K | 26,673 | — | ↗ |
| 2024-03-14 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 44.02 | 770.4K | 194,870 | — | ↗ |
| 2024-03-13 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 17,500 | 44.67 | 781.7K | 194,870 | — | ↗ |
| 2024-03-11 | Halpin Michael | Officer | S-Sale | D | Common Stock | 7,874 | 44.71 | 352.0K | 949 | — | ↗ |
| 2024-03-08 | Flynn Sean C. | Officer | S-Sale | D | Common Stock | 8,115 | 45.33 | 367.9K | 167 | — | ↗ |
| 2024-03-07 | SIEGAL JONATHAN | Officer | S-Sale | D | Common Stock | 1,634 | 45.00 | 73.5K | 1,400 | — | ↗ |
| 2024-02-22 | SIEGAL JONATHAN | Officer | A-Award | A | Stock Option (Right to Buy) | 7,500 | 48.31 | 362.3K | 7,500 | — | ↗ |
| 2024-02-22 | Mara Joseph Anthony Jr | Officer | A-Award | A | Stock Option (Right to Buy) | 46,250 | 48.31 | 2.23M | 46,250 | — | ↗ |
| 2024-02-22 | Hopper Jonathan Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 30,000 | 48.31 | 1.45M | 30,000 | — | ↗ |
| 2024-02-22 | Halpin Michael | Officer | A-Award | A | Restricted Stock Unit | 21,000 | 0.00 | — | 21,000 | — | ↗ |
| 2024-02-22 | Flynn Sean C. | Officer | A-Award | A | Restricted Stock Unit | 12,000 | 0.00 | — | 12,000 | — | ↗ |
| 2024-02-22 | Colangelo Dominick | Director / Officer | A-Award | A | Restricted Stock Unit | 73,000 | 0.00 | — | 73,000 | — | ↗ |
| 2024-02-20 | ZERBE ROBERT L MD | Director | M-Exempt | A | Common Stock | 722 | 3.74 | 2.7K | 24,117 | — | ↗ |
| 2024-02-20 | SIEGAL JONATHAN | Officer | M-Exempt | A | Restricted Stock Unit | 2,500 | 0.00 | — | 7,500 | — | ↗ |
| 2024-02-20 | Mara Joseph Anthony Jr | Officer | M-Exempt | A | Common Stock | 4,625 | 0.00 | — | 18,801 | — | ↗ |
| 2024-02-20 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 1,750 | 0.00 | — | 58,695 | — | ↗ |
| 2024-02-20 | Halpin Michael | Officer | M-Exempt | A | Restricted Stock Unit | 5,250 | 0.00 | — | 15,750 | — | ↗ |
| 2024-02-20 | Flynn Sean C. | Officer | M-Exempt | A | Common Stock | 1,750 | 0.00 | — | 9,059 | — | ↗ |
| 2024-02-20 | Colangelo Dominick | Director / Officer | M-Exempt | A | Restricted Stock Unit | 8,937 | 0.00 | — | 8,938 | — | ↗ |
| 2024-02-15 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 17,500 | 3.02 | 52.9K | 315,000 | — | ↗ |
| 2024-02-14 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 17,500 | 3.02 | 52.9K | 332,500 | — | ↗ |
| 2024-02-12 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 1,625 | 0.00 | — | 54,759 | — | ↗ |
| 2024-02-12 | Halpin Michael | Officer | F-InKind | D | Common Stock | 1,782 | 47.42 | 84.5K | 2,667 | — | ↗ |
| 2024-02-12 | Colangelo Dominick | Director / Officer | F-InKind | D | Common Stock | 3,477 | 47.42 | 164.9K | 174,008 | — | ↗ |
| 2024-01-29 | ZERBE ROBERT L MD | Director | S-Sale | D | Common Stock | 2,300 | 44.22 | 101.7K | 23,395 | — | ↗ |
| 2024-01-25 | ZERBE ROBERT L MD | Director | S-Sale | D | Common Stock | 200 | 44.02 | 8.8K | 25,695 | — | ↗ |
| 2024-01-22 | ZERBE ROBERT L MD | Director | M-Exempt | A | Common Stock | 3,000 | 4.12 | 12.4K | 28,895 | — | ↗ |
| 2024-01-18 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 16,726 | 3.02 | 50.5K | 350,000 | — | ↗ |
| 2024-01-17 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 16,726 | 3.02 | 50.5K | 366,726 | — | ↗ |
| 2024-01-12 | ZERBE ROBERT L MD | Director | S-Sale | D | Common Stock | 2,200 | 38.09 | 83.8K | 30,895 | — | ↗ |
| 2023-12-31 | SIEGAL JONATHAN | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-31 | Mara Joseph Anthony Jr | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-12-14 | Wotton Paul K | Director | S-Sale | D | Common Stock | 5,000 | 37.31 | 186.6K | 26,802 | — | ↗ |
| 2023-12-14 | Flynn Sean C. | Officer | S-Sale | D | Common Stock | 106 | 37.45 | 4.0K | 4,467 | — | ↗ |
| 2023-12-14 | Colangelo Dominick | Director / Officer | M-Exempt | A | Common Stock | 12,000 | 3.57 | 42.8K | 181,985 | — | ↗ |
| 2023-12-13 | Flynn Sean C. | Officer | S-Sale | D | Common Stock | 1,432 | 34.20 | 49.0K | 4,573 | — | ↗ |
| 2023-12-13 | Colangelo Dominick | Director / Officer | S-Sale | D | Common Stock | 12,000 | 34.03 | 408.4K | 169,985 | — | ↗ |
| 2023-12-07 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 12,000 | 3.57 | 42.8K | 24,000 | — | ↗ |
| 2023-12-06 | Colangelo Dominick | Director / Officer | M-Exempt | A | Stock Option (Right to Buy) | 12,397 | 3.57 | 44.3K | 36,000 | — | ↗ |
| 2023-11-30 | Halpin Michael | Officer | M-Exempt | A | Common Stock | 17,447 | 7.20 | 125.6K | 18,274 | — | ↗ |
| 2023-11-20 | Hopper Jonathan Mark | Officer | M-Exempt | A | Common Stock | 5,000 | 10.95 | 54.8K | 58,007 | — | ↗ |
| 2023-11-15 | ZERBE ROBERT L MD | Director | S-Sale | D | Common Stock | 100 | 38.06 | 3.8K | 33,095 | — | ↗ |
| 2023-11-15 | SIEGAL JONATHAN | Officer | S-Sale | D | Common Stock | 662 | 37.70 | 25.0K | 1,305 | — | ↗ |
| 2023-11-15 | Flynn Sean C. | Officer | G-Gift | D | Common Stock | 1,042 | 0.00 | — | 6,005 | — | ↗ |
| 2023-10-02 | SIEGAL JONATHAN | Officer | M-Exempt | A | Common Stock | 938 | 0.00 | — | 2,134 | — | ↗ |
| 2023-08-04 | Halpin Michael | Officer | G-Gift | A | Common Stock | 16,359 | 0.00 | — | 16,359 | — | ↗ |
| 2023-07-14 | ZERBE ROBERT L MD | Director | S-Sale | D | Common Stock | 1,000 | 38.84 | 38.8K | 33,395 | — | ↗ |
| 2023-06-22 | ZERBE ROBERT L MD | Director | S-Sale | D | Common Stock | 3,000 | 36.00 | 108.0K | 34,395 | — | ↗ |
| 2023-06-01 | WRIGHT LISA | Director | M-Exempt | A | Common Stock | 433 | 0.00 | — | 5,817 | — | ↗ |
| 2023-05-03 | ZERBE ROBERT L MD | Director | A-Award | A | Stock Option (right to buy) | 8,000 | 32.12 | 257.0K | 8,000 | — | ↗ |
Executive team
Top executives
EBIT / Employee
53.0K
Shares Outstanding
50.93M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | Dominick Colangelo President and CEO | 860.0K | — | 3.96M | 5.46M | 860.0K | 15.5K | 11.16M | 84.44% | ↗ |
| 2 | 2025 | Michael Halpin Chief Operating Officer | 562.0K | — | 1.14M | 1.57M | 337.2K | 14.7K | 3.62M | 74.78% | ↗ |
| 3 | 2025 | Joe Mara Chief Financial Officer | 525.0K | — | 1.00M | 1.38M | 315.0K | 14.9K | 3.24M | 73.63% | ↗ |
| 4 | 2025 | Jonathan Hopper Chief Medical Officer | 494.0K | — | 760.3K | 1.05M | 247.0K | 14.9K | 2.56M | 70.50% | ↗ |
| 5 | 2025 | Sean Flynn Chief Legal Officer | 484.0K | — | 760.3K | 1.05M | 242.0K | 14.7K | 2.55M | 70.92% | ↗ |
| 6 | 2024 | Dominick Colangelo President and CEO | 830.0K | — | 3.53M | 5.15M | 712.6K | 14.5K | 10.24M | 84.79% | ↗ |
| 7 | 2024 | Michael Halpin Chief Operating Officer | 535.0K | — | 1.01M | 1.48M | 270.2K | 14.0K | 3.32M | 75.30% | ↗ |
| 8 | 2024 | Karen Mahoney Chief Human Resources Officer | 186.2K | — | 541.6K | 2.16M | 88.8K | 5.9K | 2.98M | 90.57% | ↗ |
| 9 | 2024 | Joe Mara Chief Financial Officer | 505.0K | — | 893.7K | 1.31M | 255.0K | 14.2K | 2.97M | 73.97% | ↗ |
| 10 | 2024 | Jonathan Hopper Chief Medical Officer | 475.0K | — | 579.7K | 847.2K | 215.9K | 14.2K | 2.13M | 66.93% | ↗ |
| 11 | 2024 | Sean Flynn Chief Legal Officer | 465.0K | — | 579.7K | 847.2K | 211.3K | 14.0K | 2.12M | 67.40% | ↗ |
| 12 | 2023 | Dominick Colangelo President and CEO | 790.0K | — | 2.18M | 3.34M | 738.7K | 14.6K | 7.06M | 78.13% | ↗ |
| 13 | 2023 | Michael Halpin Chief Operating Officer | 505.0K | — | 626.2K | 959.7K | 277.8K | 14.1K | 2.38M | 66.56% | ↗ |
| 14 | 2023 | Joe Mara Chief Financial Officer | 475.0K | — | 551.7K | 845.5K | 261.3K | 14.3K | 2.15M | 65.05% | ↗ |
| 15 | 2023 | Jonathan Hopper Chief Medical Officer | 440.0K | — | 357.8K | 548.4K | 217.8K | 14.4K | 1.58M | 57.42% | ↗ |
| 16 | 2023 | Sean Flynn SVP, General Counsel and Secretary | 430.0K | — | 357.8K | 548.4K | 212.9K | 14.1K | 1.56M | 57.97% | ↗ |
| 17 | 2023 | Sean Flynn Chief Legal Officer | 430.0K | — | 357.8K | 548.4K | 212.9K | 14.1K | 1.56M | 57.97% | ↗ |
| 18 | 2022 | Dominick Colangelo President and CEO | 760.0K | — | 1.63M | 5.66M | 646.0K | 13.8K | 8.71M | 83.70% | ↗ |
| 19 | 2022 | Michael Halpin Chief Operating Officer | 470.0K | — | 534.0K | 1.85M | 235.0K | 13.2K | 3.10M | 76.84% | ↗ |
| 20 | 2022 | Joe Mara Chief Financial Officer | 440.0K | — | 384.5K | 1.33M | 220.0K | 13.4K | 2.39M | 71.81% | ↗ |
| 21 | 2022 | Jonathan Hopper Chief Medical Officer | 415.0K | — | 324.6K | 1.12M | 186.8K | 13.5K | 2.06M | 70.19% | ↗ |
| 22 | 2022 | Sean Flynn Chief Legal Officer | 400.0K | — | 324.6K | 1.12M | 180.0K | 13.2K | 2.04M | 70.94% | ↗ |
| 23 | 2022 | Sean Flynn SVP, General Counsel and Secretary | 400.0K | — | 324.6K | 1.12M | 180.0K | 13.2K | 2.04M | 70.94% | ↗ |
| 24 | 2021 | Dominick C. Colangelo President and CEO | 730.0K | — | 1.84M | 9.98M | 620.5K | 13.4K | 13.18M | 89.65% | ↗ |
| 25 | 2021 | Dominick Colangelo President and CEO | 730.0K | — | 1.84M | 9.98M | 620.5K | 13.4K | 13.18M | 89.65% | ↗ |
| 26 | 2021 | Joe Mara Chief Financial Officer | 383.1K | 50.0K | 698.1K | 4.44M | 193.3K | 9.9K | 5.77M | 88.98% | ↗ |
| 27 | 2021 | Michael Halpin Chief Operating Officer | 440.0K | — | 578.3K | 3.33M | 220.0K | 12.9K | 4.58M | 85.30% | ↗ |
| 28 | 2021 | Jonathan Hopper Chief Medical Officer | 390.0K | — | 359.8K | 2.00M | 175.5K | 12.9K | 2.93M | 80.29% | ↗ |
| 29 | 2021 | Sean C. Flynn SVP, General Counsel and Secretary | 375.0K | — | 359.8K | 2.00M | 168.8K | 12.9K | 2.91M | 80.89% | ↗ |
| 30 | 2021 | Sean Flynn SVP, General Counsel and Secretary | 375.0K | — | 359.8K | 2.00M | 168.8K | 12.9K | 2.91M | 80.89% | ↗ |
| 31 | 2021 | Sandra Pennell Former Vice President and Controller | 121.3K | — | 141.4K | 831.8K | — | 5.5K | 1.10M | 88.48% | ↗ |
| 32 | 2020 | Dominick C. Colangelo President and CEO | 675.0K | — | 540.0K | 2.68M | 506.3K | 12.7K | 4.41M | 72.94% | ↗ |
| 33 | 2020 | Dominick Colangelo President and CEO | 675.0K | — | 540.0K | 2.68M | 506.3K | 12.7K | 4.41M | 72.94% | ↗ |
| 34 | 2020 | Michael Halpin Chief Operating Officer | 395.0K | — | 252.0K | 1.25M | 177.8K | 12.7K | 2.09M | 71.96% | ↗ |
| 35 | 2020 | Gerard Michel Former CFO and VP of Corporate Development | 315.4K | — | 216.0K | 1.07M | — | 12.0K | 1.61M | 79.73% | ↗ |
| 36 | 2020 | Jonathan Hopper Chief Medical Officer | 365.0K | — | 117.0K | 580.4K | 146.0K | 12.7K | 1.22M | 57.11% | ↗ |
| 37 | 2020 | Sean C. Flynn VP, General Counsel and Secretary | 350.0K | — | — | — | 140.0K | 12.7K | 502.7K | 0.00% | ↗ |
| 38 | 2020 | Sean Flynn SVP, General Counsel and Secretary | 350.0K | — | — | — | 140.0K | 12.7K | 502.7K | 0.00% | ↗ |
| 39 | 2020 | Sean C. Flynn SVP, General Counsel and Secretary | 350.0K | — | — | — | 140.0K | 12.7K | 502.7K | 0.00% | ↗ |
| 40 | 2020 | Sandra Pennell Former Vice President and Controller | 204.3K | — | 14.5K | 73.4K | 63.4K | 9.2K | 364.9K | 24.10% | ↗ |
| 41 | 2020 | Sandra Pennell Vice President and Controller | 204.3K | — | 14.5K | 73.4K | 63.4K | 9.2K | 364.9K | 24.10% | ↗ |
| 42 | 2019 | Dominick C. Colangelo President and CEO | 634.0K | — | 462.3K | 3.77M | 510.4K | 12.5K | 5.39M | 78.52% | ↗ |
| 43 | 2019 | Gerard Michel Former CFO and VP of Corporate Development | 398.0K | — | 199.9K | 1.49M | 206.0K | 12.5K | 2.30M | 73.25% | ↗ |
| 44 | 2019 | Gerard Michel CFO and VP of Corporate Development | 398.0K | — | 199.9K | 1.49M | 206.0K | 12.5K | 2.30M | 73.25% | ↗ |
| 45 | 2019 | Daniel Orlando Former Chief Operating Officer | 177.7K | — | 233.2K | 1.70M | — | 7.4K | 2.12M | 91.27% | ↗ |
| 46 | 2019 | Michael Halpin Chief Operating Officer | 370.0K | — | 125.0K | 926.4K | 185.6K | 12.5K | 1.62M | 64.92% | ↗ |
| 47 | 2018 | Dominick C. Colangelo President and CEO | 592.0K | 106.6K | — | 1.55M | 355.2K | 11.8K | 2.61M | 59.24% | ↗ |
| 48 | 2018 | Gerard Michel CFO and VP of Corporate Development | 386.0K | 46.3K | — | 516.2K | 154.4K | 11.8K | 1.11M | 46.31% | ↗ |
| 49 | 2018 | Gerard Michel Former CFO and VP of Corporate Development | 386.0K | 46.3K | — | 516.2K | 154.4K | 11.8K | 1.11M | 46.31% | ↗ |
| 50 | 2018 | Daniel Orlando Chief Operating Officer | 357.0K | 42.8K | — | 516.2K | 142.8K | 11.8K | 1.07M | 48.21% | ↗ |
| 51 | 2018 | Daniel Orlando Former Chief Operating Officer | 357.0K | 42.8K | — | 516.2K | 142.8K | 11.8K | 1.07M | 48.21% | ↗ |
| 52 | 2017 | Dominick C. Colangelo President and CEO | 555.5K | — | — | 573.6K | 333.3K | 11.7K | 1.47M | 38.91% | ↗ |
| 53 | 2017 | Gerard Michel CFO and VP of Corporate Development | 374.0K | — | — | 191.2K | 149.6K | 11.6K | 726.4K | 26.32% | ↗ |
| 54 | 2017 | Daniel Orlando Chief Operating Officer | 345.0K | — | — | 191.2K | 138.0K | 11.6K | 685.8K | 27.88% | ↗ |
| 55 | 2017 | Daniel Orlando Former Chief Operating Officer | 345.0K | — | — | 191.2K | 138.0K | 11.6K | 685.8K | 27.88% | ↗ |
| 56 | 2016 | Dominick C. Colangelo President and CEO | 505.0K | — | — | 219.5K | 272.7K | 11.3K | 1.01M | 21.76% | ↗ |
| 57 | 2016 | Gerard Michel CFO and VP of Corporate Development | 365.0K | — | — | 106.4K | 131.4K | 11.3K | 614.1K | 17.33% | ↗ |
| 58 | 2016 | Daniel Orlando Chief Operating Officer | 330.0K | — | — | 106.4K | 118.8K | 11.3K | 566.5K | 18.78% | ↗ |
| 59 | 2015 | Dominick C. Colangelo President and CEO | 485.0K | — | — | 954.8K | 247.4K | 11.3K | 1.70M | 56.22% | ↗ |
| 60 | 2015 | Gerard Michel CFO and VP of Corporate Development | 356.0K | — | — | 390.6K | 121.0K | 140.0K | 1.01M | 38.76% | ↗ |
| 61 | 2015 | Daniel Orlando Chief Operating Officer | 320.0K | — | — | 416.6K | 108.8K | 11.3K | 856.7K | 48.63% | ↗ |
| 62 | 2014 | Dominick C. Colangelo President and CEO | 430.0K | 89.6K | — | 140.2K | 236.5K | 39.6K | 914.4K | 15.33% | ↗ |
| 63 | 2014 | Dominick C. Colangelo President and CEO | 430.0K | — | — | 140.2K | 236.5K | 11.1K | 817.9K | 17.15% | ↗ |
| 64 | 2014 | Daniel Orlando Chief Operating Officer | 292.1K | 45.6K | — | 84.1K | 117.4K | 37.5K | 576.7K | 14.59% | ↗ |
| 65 | 2014 | Daniel Orlando Chief Operating Officer | 292.1K | — | — | 84.1K | 117.4K | 11.1K | 504.8K | 16.67% | ↗ |
| 66 | 2014 | Gerard Michel CFO and VP of Corporate Development | 204.2K | — | — | 146.3K | 82.8K | 19.0K | 452.3K | 32.34% | ↗ |
| 67 | 2014 | Gerard Michel CFO and VP of Corporate Development | 204.2K | — | — | 146.3K | 82.8K | 1.7K | 434.9K | 33.62% | ↗ |
| 68 | 2013 | Dominick C. Colangelo President and CEO | 358.3K | — | — | 937.9K | 89.6K | 59.3K | 1.45M | 64.90% | ↗ |
| 69 | 2013 | Dominick C. Colangelo President and CEO | 358.3K | — | — | 937.9K | 89.6K | 59.3K | 1.45M | 64.90% | ↗ |
| 70 | 2013 | Daniel R. Orlando, Chief Operating Officer | 285.0K | 35.0K | — | — | 45.6K | 46.6K | 412.2K | 0.00% | ↗ |
| 71 | 2013 | Daniel Orlando Chief Operating Officer | 285.0K | 35.0K | — | — | 45.6K | 46.6K | 412.2K | 0.00% | ↗ |
| 72 | 2013 | Daniel Orlando Chief Operating Officer | 285.0K | 35.0K | — | — | 45.6K | 46.6K | 412.2K | 0.00% | ↗ |
| 73 | 2013 | Ronnda L. Bartel, Chief Scientific Officer | 260.0K | — | — | — | — | 28.9K | 288.9K | 0.00% | ↗ |
| 74 | 2013 | Ronnda L. Bartel, Former Chief Scientific Officer | 260.0K | — | — | — | — | 28.9K | 288.9K | 0.00% | ↗ |
| 75 | 2013 | Sharon M. Watling, Former Vice President Clinical Development | 79.8K | — | — | — | — | 185.3K | 265.1K | 0.00% | ↗ |
| 76 | 2013 | Brian D. Gibson, Former Vice President of Finance, Chief Accounting | 110.0K | — | — | — | — | 32.4K | 142.4K | 0.00% | ↗ |
| 77 | 2013 | Michael W. Elliston, Former Controller, Chief Accounting Officer and Treasurer | 113.5K | — | — | — | 17.5K | 4.8K | 135.8K | 0.00% | ↗ |
| 78 | 2013 | Michael W. Elliston, Controller, Chief Accounting Officer and Treasurer | 113.5K | — | — | — | 17.5K | 4.8K | 135.8K | 0.00% | ↗ |
| 79 | 2013 | Tim M. Mayleben Former President and CEO | — | — | — | — | — | — | — | — | ↗ |
| 80 | 2013 | Gerard Michel CFO and VP of Corporate Development | — | — | — | — | — | — | — | — | ↗ |
| 81 | 2012 | Tim M. Mayleben Former President and CEO | 407.3K | — | — | 875.2K | — | 44.4K | 1.33M | 65.96% | ↗ |
| 82 | 2012 | Daniel R. Orlando, Chief Operating Officer | 99.9K | — | — | 485.5K | — | 443.00 | 585.9K | 82.86% | ↗ |
| 83 | 2012 | Brian D. Gibson, Former Vice President of Finance, Chief Accounting | 165.0K | — | — | 319.4K | — | 21.1K | 505.5K | 63.18% | ↗ |
| 84 | 2012 | Ronnda L. Bartel, Former Chief Scientific Officer | 253.1K | — | — | 209.2K | — | 9.6K | 471.9K | 44.33% | ↗ |
| 85 | 2012 | Ronnda L. Bartel, Chief Scientific Officer | 253.1K | — | — | 209.2K | — | 9.6K | 471.9K | 44.33% | ↗ |
| 86 | 2012 | Sharon M. Watling, Former Vice President Clinical Development | 245.0K | — | — | 199.1K | — | 10.4K | 454.5K | 43.80% | ↗ |
| 87 | 2012 | Dominick C. Colangelo President and CEO | — | — | — | — | — | — | — | — | ↗ |
| 88 | 2012 | Michael W. Elliston, Former Controller, Chief Accounting Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 89 | 2012 | Michael W. Elliston, Controller, Chief Accounting Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 90 | 2011 | Tim M. Mayleben Former President and CEO | 425.0K | 23.8K | — | — | 191.3K | 11.4K | 1.71M | 0.00% | ↗ |
| 91 | 2011 | Sharon M. Watling, Former Vice President Clinical Development | 210.6K | — | — | 333.2K | 70.0K | 9.7K | 623.5K | 53.44% | ↗ |
| 92 | 2011 | Ronnda L. Bartel, Chief Scientific Officer | 243.4K | 14.8K | — | — | 85.2K | 7.1K | 586.5K | 0.00% | ↗ |
| 93 | 2011 | Ronnda L. Bartel, Former Chief Scientific Officer | 243.4K | 14.8K | — | — | 85.2K | 7.1K | 586.5K | 0.00% | ↗ |
| 94 | 2011 | Brian D. Gibson, Former Vice President of Finance, Chief Accounting | 123.3K | — | — | 105.5K | 40.0K | 6.5K | 275.3K | 38.33% | ↗ |
| 95 | 2011 | Daniel R. Orlando, Chief Operating Officer | — | — | — | — | — | — | — | — | ↗ |
| 96 | 2011 | Michael W. Elliston, Former Controller, Chief Accounting Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 97 | 2011 | Michael W. Elliston, Controller, Chief Accounting Officer and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 98 | 2011 | Dominick C. Colangelo President and CEO | — | — | — | — | — | — | — | — | ↗ |
| 99 | 2010 | President and CEO | 233.4K | 8.4K | — | — | 111.6K | 76.9K | 1.25M | 0.00% | ↗ |
| 100 | 2010 | Timothy M. Mayleben, | 212.5K | 4.4K | — | — | 95.6K | 12.0K | 699.0K | 0.00% | ↗ |
| 101 | 2010 | Chief Scientific Officer | 243.4K | 40.0K | — | — | — | 8.1K | 460.5K | 0.00% | ↗ |
| 102 | 2010 | Scott C. Durbin, | 137.5K | 1.9K | — | — | 48.1K | 7.3K | 289.6K | 0.00% | ↗ |
| 103 | 2010 | Ronnda L. Bartel, Chief Scientific Officer | 121.7K | 40.0K | — | — | — | 4.2K | 288.2K | 0.00% | ↗ |
| 104 | 2010 | Chief Financial Officer | 18.8K | — | — | — | — | — | 277.5K | 0.00% | ↗ |
| 105 | 2003 | R. Douglas Armstrong, Ph.D. President and Chief Executive Officer, Chairman of the Board of Directors | 280.5K | — | — | — | — | 14.0K | 294.5K | 0.00% | ↗ |
| 106 | 2003 | Steven N. Wolff, M.D. Vice President Medical Research | 210.0K | — | — | — | — | — | 210.0K | 0.00% | ↗ |
| 107 | 2003 | Alan M. Wright | 181.8K | — | — | — | — | — | 181.8K | 0.00% | ↗ |
| 108 | 2003 | Brian S. Hampson Vice President Product Development | 165.0K | — | — | — | — | — | 165.0K | 0.00% | ↗ |
| 109 | 2003 | Robert J. Bard, J.D., R.A.C. | 126.3K | — | — | — | — | — | 126.3K | 0.00% | ↗ |
| 110 | 2002 | R. Douglas Armstrong, Ph.D. President and Chief Executive Officer, Chairman of the Board of Directors | 275.0K | 87.5K | — | — | — | 21.7K | 384.2K | 0.00% | ↗ |
| 111 | 2002 | Steven N. Wolff, M.D. Vice President, Medical Research | 210.0K | — | — | — | — | — | 210.0K | 0.00% | ↗ |
| 112 | 2002 | Steven N. Wolff, M.D. Vice President Medical Research | 210.0K | — | — | — | — | — | 210.0K | 0.00% | ↗ |
| 113 | 2002 | Bruce W. Husel Vice President, Quality Systems and Regulatory Affairs | 145.6K | — | — | — | — | 11.2K | 156.8K | 0.00% | ↗ |
| 114 | 2002 | Brian S. Hampson Vice President Product Development | 150.0K | — | — | — | — | — | 150.0K | 0.00% | ↗ |
| 115 | 2002 | Brian S. Hampson Vice President, Product Development | 150.0K | — | — | — | — | — | 150.0K | 0.00% | ↗ |
| 116 | 2002 | Michael S. Durski Vice President, Finance and Administration, Chief Financial Officer, Secretary and Treasurer | 68.1K | — | — | — | — | — | 68.1K | 0.00% | ↗ |
| 117 | 2001 | To dd E. Simpson Vic e President, Finance Administration, Chief Financial Officer, Secretary and Treasurer | 166.2K | 107.5K | — | 100.0K | — | — | 273.7K | 36.54% | ↗ |
| 118 | 2001 | R. Douglas Armstrong, Ph.D. Pre sident and Chief Executive Officer, Ch airman of the Board of Directors | 250.0K | — | — | 500.0K | — | — | 250.0K | 200.00% | ↗ |
| 119 | 2001 | R. Douglas Armstrong, Ph.D. President and Chief Executive Officer, Chairman of the Board of Directors | 250.0K | — | — | — | — | — | 250.0K | 0.00% | ↗ |
| 120 | 2001 | Brian S. Hampson Vice President, Product Development | 127.1K | 44.0K | — | — | — | — | 171.1K | 0.00% | ↗ |
| 121 | 2001 | Bri an S. Hampson Vic e President, Product Development | 127.1K | 44.0K | — | 100.0K | — | — | 171.1K | 58.45% | ↗ |
| 122 | 2001 | Brian S. Hampson Vice President Product Development | 127.1K | 44.0K | — | — | — | — | 171.1K | 0.00% | ↗ |
| 123 | 2001 | Bruce W. Husel Vice President, Quality Systems and Regulatory Affairs | 140.9K | 7.0K | — | — | — | — | 147.9K | 0.00% | ↗ |
| 124 | 2001 | Bru ce W. Husel Vic e President, Quality Systems and Re gulatory Affairs | 140.9K | 7.0K | — | 100.0K | — | — | 147.9K | 67.60% | ↗ |
| 125 | 2001 | Steven N. Wolff, M.D. Vice President Medical Research | 48.1K | — | — | — | — | — | 48.1K | 0.00% | ↗ |
| 126 | 2001 | Steven N. Wolff, M.D. Vice President, Medical Research | 48.1K | — | — | — | — | — | 48.1K | 0.00% | ↗ |
| 127 | 2001 | Michael S. Durski Vice President, Finance and Administration, Chief Financial Officer, Secretary and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 128 | 2000 | R. Douglas Armstrong, Ph.D. President and Chief Executive Officer, Chairman of the Board of Directors | 233.3K | 262.5K | — | — | — | — | 495.8K | 0.00% | ↗ |
| 129 | 2000 | R. Douglas Armstrong, Ph.D. Pre sident and Chief Executive Officer, Ch airman of the Board of Directors | 233.3K | 262.5K | — | 317.0K | — | — | 495.8K | 63.93% | ↗ |
| 130 | 2000 | To dd E. Simpson Vic e President, Finance Administration, Chief Financial Officer, Secretary and Treasurer | 152.5K | 8.3K | — | 193.0K | — | 11.0K | 171.7K | 112.40% | ↗ |
| 131 | 2000 | Brian S. Hampson Vice President, Product Development | 103.3K | 56.3K | — | — | — | — | 159.5K | 0.00% | ↗ |
| 132 | 2000 | Bri an S. Hampson Vic e President, Product Development | 103.3K | 56.3K | — | 54.0K | — | — | 159.5K | 33.85% | ↗ |
| 133 | 2000 | Bruce W. Husel Vice President, Quality Systems and Regulatory Affairs | 127.5K | 26.5K | — | — | — | — | 154.0K | 0.00% | ↗ |
| 134 | 2000 | Bru ce W. Husel Vic e President, Quality Systems and Re gulatory Affairs | 127.5K | 26.5K | — | 85.0K | — | — | 154.0K | 55.18% | ↗ |
| 135 | 2000 | Michael S. Durski Vice President, Finance and Administration, Chief Financial Officer, Secretary and Treasurer | — | — | — | — | — | — | — | — | ↗ |
| 136 | 1999 | R. Douglas Armstrong, Ph.D. Pre sident and Chief Executive Officer, Ch airman of the Board of Directors | 244.2K | — | — | 317.0K | — | 22.0K | 266.2K | 119.08% | ↗ |
| 137 | 1999 | To dd E. Simpson Vic e President, Finance Administration, Chief Financial Officer, Secretary and Treasurer | 150.0K | — | — | 50.0K | — | — | 150.0K | 33.33% | ↗ |
| 138 | 1999 | Bru ce W. Husel Vic e President, Quality Systems and Re gulatory Affairs | 125.0K | — | — | 50.0K | — | — | 125.0K | 40.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Dominick C. Colangelo | Chief Executive Officer, President & Director | 2M | male |
| Michael Halpin | Chief Operating Officer | 913.9K | male |
| Joseph Anthony Mara Jr. | Chief Financial Officer & Treasurer | 854.9K | male |
| Jonathan Hopper FRCSEd. | Chief Medical Officer | 755.9K | — |
| Sean C. Flynn | Chief Legal Officer | 740.7K | male |
| Karen Mahoney | Chief Human Resources Officer | 514.4K | female |
| Eric Burns | Vice President of Finance & Investor Relations | — | male |
| Mike Gilligan | Senior Vice President of Sales | — | male |
| Patrick Helfrich | Vice President of Marketing & Commercial Strategy | — | male |
| Patrick J. Fowler | Senior Vice President of Corporate Development & Strategy | — | male |
| Roland DeAngelis | Chief Marketing Officer | — | male |
| Jonathan Siegal | Principal Accounting Officer, Vice President & Corporate Controller | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for VCEL
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
